The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit

Giancarlo Ceccarelli, Alessandra Oliva, Gabriella d'Ettorre, Alessandra D'Abramo, Elena Caresta, Caterina Silvia Barbara, Maria Teresa Mascellino, Paola Papoff, Corrado Moretti, Vincenzo Vullo, Paolo Visca, Mario Venditti

Research output: Contribution to journalArticle

Abstract

Background: Acinetobacter baumannii has been associated with high morbidity and mortality rates, even in pediatric patients. Therapeutic options are limited, especially when the strain is multidrug resistant. Methods: Clinical and microbiological analyses of 4 cases of systemic infections caused by multi drug resistant A. baumannii treated with colistin/vancomycin combination at a Pediatric Intensive Care Unit were performed in order to explore the potential synergistic activity of colistin plus vancomycin. All the patients were treated with colistin, meropenem and vancomycin. Results: Four severe infections due to MDR A. baumannii were observed. All patients treated with colistin/vancomycin combination had a positive outcome with no infection relapses. Most importantly, no significant adverse events related to the simultaneous administration of COL plus VAN were observed. In our in-vitro experiments, the synergistic effect of the combination COL plus VAN showed an early bactericidal activity even at VAN concentration of 16 mg/L, which reflects the serum trough concentrations obtained in patients. Discussion: An antimicrobial strategy based on the activity of colistin plus vancomycin was in-vitro and in-vivo effective in life-threatening infections caused by multidrug-resistant A. baumannii in a Pediatric Intensive Care Unit, in the absence of adverse effects. Colistin plus vancomycin were highly synergic and bactericidal against carbapenem-resistant, colistin sensitive A. baumannii whereas the addition of meropenem did not enhance the in-vitro activity of colistin plus vancomycin. Conclusions: Our results confirm existing data on the potential synergistic activity of a therapeutic strategy including colistin plus vancomycin and provide important new clinical information for its potential use as a therapeutic option against MDR A. baumannii infections, especially in the pediatric population.

Original languageEnglish
Article number393
Pages (from-to)1-8
Number of pages8
JournalBMC Infectious Diseases
Volume15
Issue number1
DOIs
Publication statusPublished - Sep 30 2015

Keywords

  • Acinetobacter baumannii
  • Colistin
  • Multidrug resistant gram negatives
  • Pediatric Intensive Care Unit (PICU)
  • Synergism
  • Vancomycin

ASJC Scopus subject areas

  • Infectious Diseases

Fingerprint Dive into the research topics of 'The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit'. Together they form a unique fingerprint.

  • Cite this

    Ceccarelli, G., Oliva, A., d'Ettorre, G., D'Abramo, A., Caresta, E., Barbara, C. S., Mascellino, M. T., Papoff, P., Moretti, C., Vullo, V., Visca, P., & Venditti, M. (2015). The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit. BMC Infectious Diseases, 15(1), 1-8. [393]. https://doi.org/10.1186/s12879-015-1133-3